BSG and ovarian cancer: It has been found that the serum CD147 level of ovarian cancer patients is significantly higher than that of patients with benign ovarian diseases and is associated with the prognosis of patients’ recurrence, which may be due to the fact that CD147 can activate matrix metalloproteinases (MMPs) and degrade the extracellular matrix of tumor cells, thus inducing invasion and metastasis of tumor cells and then promoting the recurrence of tumors (17).